The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy

다국어 초록 (Multilingual Abstract)

Purpose Despite the successful use of tyrosine kinase inhibitors (TKIs) in cancer patients, their effect on herpes zoster development has not been studied. The aim of this study was to evaluate and compare the effects of epidermal growth factor receptor (EGFR) TKI and cytotoxic chemotherapy on the risk of herpes zoster development in non-small cell lung cancer (NSCLC) patients.
Materials and Methods We conducted a medical review of all eligible NSCLC patients in Seoul National University hospital between 2002 and 2015. We classified patients based on whether they previously underwent EGFR TKI therapy into either the TKI group or the cytotoxic group. We compared the incidence rates of herpes zoster during TKI therapy and cytotoxic chemotherapy. Additionally, the longitudinal risk of herpes zoster from TKIs was analyzed using the incidence rate ratio (IRR) of the TKI group to the cytotoxic group and the log-rank test of the Kaplan- Meier method.
Results Of the 2,981 NSCLC patients, 54 patients (1.54%) developed herpes zoster. In the TKI group (2,002 patients), the IRR of herpes zoster during TKI therapy compared to that during cytotoxic chemotherapy was 1.05 (95% confidence interval [CI], 0.53 to 2.09). The IRR of the TKI group compared to the cytotoxic group was 1.33 (95% CI, 0.64 to 2.76). The Kaplan- Meier cumulative risk of both groups was not significantly different.
Conclusion Our results show that the incidence rate of herpes zoster in the TKI group was not statistically different from the incidence in the cytotoxic group during and after chemotherapy in NSCLC patients.

참고문헌 (Reference)

1 Thomas SL, "What does epidemiology tell us about risk factors for herpes zoster?" 4 : 26-33, 2004

2 Rusthoven JJ, "Varicella-zoster infection in adult cancer patients : a population study" 148 : 1561-1566, 1988

3 Schimpff S, "Varicella-Zoster infection in patients with cancer" 76 : 241-254, 1972

4 Cataldo VD, "Treatment of non-small-cell lung cancer with erlotinib or gefitinib" 364 : 947-955, 2011

5 Wnorowski AM, "The management of EGFR inhibitor adverse events : a case series and treatment paradigm" 51 : 223-232, 2012

6 Yenikomshian MA, "The epidemiology of herpes zoster and its complications in Medicare cancer patients" 15 : 106-, 2015

7 Rifkind D, "The activation of varicella-zoster virus infections by immunosuppressive therapy" 68 : 463-474, 1966

8 Sawyers C, "Targeted cancer therapy" 432 : 294-297, 2004

9 Kozuki T, "Skin problems and EGFR-tyrosine kinase inhibitor" 46 : 291-298, 2016

10 Pinchinat S, "Similar herpes zoster incidence across Europe : results from a systematic literature review" 13 : 170-, 2013

11 Bui N, "Reactivation of hepatitis B virus after withdrawal of erlotinib" 22 : 430-432, 2015

12 김범석, "Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors" 대한암학회 46 (46): 323-330, 2014

13 Weinstein IB, "Mechanisms of disease : Oncogene addiction : a rationale for molecular targeting in cancer therapy" 3 : 448-457, 2006

14 Cho SF, "Longitudinal risk of herpes zoster in patients with non-Hodgkin lymphoma receiving chemotherapy : a nationwide population-based study" 5 : 14008-, 2015

15 Woodworth CD, "Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by human papillomavirus type 16" 421 : 19-27, 2011

16 Langhammer S, "Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib(Iressa)" 89 : 64-70, 2011

17 Neveu G, "Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly" 8 : e1002845-, 2012

18 김범석, "How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution" 대한암학회 45 (45): 178-185, 2013

19 Dunst J, "Herpes zoster in breast cancer patients after radiotherapy" 176 : 513-516, 2000

20 Masci G, "Herpes infections in breast cancer patients treated with adjuvant chemotherapy" 71 : 164-167, 2006

21 Rosell R, "Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial" 13 : 239-246, 2012

22 Weller ML, "Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6" 16 : 662-664, 2010

23 Lupberger J, "EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy" 17 : 589-595, 2011

24 Lin YH, "Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan" 28 : 1217-1220, 2010

25 Glesby MJ, "Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus" 21 : 370-375, 1995

26 Yawn BP, "A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction" 82 : 1341-1349, 2007